Oncimmune Holdings has hired Alvarez & Marsal to help secure additional financing for its trading subsidiary. The Leeds-based precision medicine company cited slower-than-expected contract conversions as a key factor in its need for funding.
The company is also exploring strategic partnerships and business synergies. Despite current financial pressures, Oncimmune stated it remains confident in its long-term prospects. It highlighted ongoing discussions for 11 projects worth over £1.8 million and potential follow-on contracts from existing clients. However, the company acknowledged uncertainty around the timing and value of these deals.
